Michael Kiehl

First-line chemoimmunotherapy with bendamustine and rituximab versus fludarabine, cyclophosphamide, and rituximab in patients with advanced chronic lymphocytic leukaemia (CLL10): an international, open-label, randomised, phase 3, non-inferiority trial

Barbara Eichhorst, Anna‐Maria Fink, Jasmin Bahlo et al. · The Lancet Oncology · 2016 · 613 citations

Hematological Malignancy, Lymphoid Neoplasia, Oncology +9

Bendamustine Combined With Rituximab in Patients With Relapsed and/or Refractory Chronic Lymphocytic Leukemia: A Multicenter Phase II Trial of the German Chronic Lymphocytic Leukemia Study Group

Kirsten Fischer, Paula Cramer, Raymonde Busch et al. · Journal of Clinical Oncology · 2011 · 372 citations

Reduced-intensity conditioning versus standard conditioning before allogeneic haemopoietic cell transplantation in patients with acute myeloid leukaemia in first complete remission: a prospective, open-label randomised phase 3 trial

Martin Bornhäuser, Joachim Kienast, Rudolf Trenschel et al. · The Lancet Oncology · 2012 · 269 citations

Hematological Malignancy, Versus Standard Conditioning, Transplantation +11

Autologous stem cell transplantation followed by a dose-reduced allograft induces high complete remission rate in multiple myeloma

Nicolaus Kröger, Rainer Schwerdtfeger, Michael Kiehl et al. · Blood · 2002 · 258 citations · Full text

Evidence of a Graft-Versus-Leukemia Effect in Chronic Lymphocytic Leukemia After Reduced-Intensity Conditioning and Allogeneic Stem-Cell Transplantation: The Cooperative German Transplant Study Group

Johannes Schetelig, Christian Thiede, Martin Bornhäuser et al. · Journal of Clinical Oncology · 2003 · 250 citations